- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: March 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in March 2027, from ClinicalTrials.gov.
Trial readouts
231 trials: 76 phase 3 (including phase 2/3) and 155 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Mar 2027 | ABX advanced biochemical compounds GmbH | [18F]PSMA-1007Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | Prostate Cancer | Phase 3 | Recruiting | NCT06122584 |
| Mar 2027 | AFT Pharmaceuticals, Ltd. | Combogesic® IV (fixed-dose combination containing acetamin…A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain | Acute Pain | Phase 3 | Recruiting | NCT07225634 |
| Mar 2027 | AbbVie | CariprazineA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric … | Depression, Bipolar I Disorder | Phase 3 | Recruiting | NCT04777357 |
| Mar 2027 | AbbVie | Risankizumab SCA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely … | Crohn's Disease | Phase 3 | Active not recruiting | NCT06063967 |
| Mar 2027 | AbbVie | UpadacitinibProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … | Systemic Lupus Erythematosus | Phase 3 | Active not recruiting | NCT05843643 |
| Mar 2027 | Ache Laboratorios Farmaceuticos S.A. | Product DNN.63.18.040, Tramal®Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain | Acute Pain | Phase 3 | Not yet recruiting | NCT07880392 |
| Mar 2027 | Amicus Therapeutics | Cipaglucosidase Alfa, MiglustatZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | Pompe Disease (Late-onset) | Phase 3 | Active not recruiting | NCT03911505 |
| Mar 2027 | Jiangsu Hengrui Medicine | –A Study of SHR-1918 In Participants With Hypertriglyceridemia | Hypertriglyceridemia | Phase 3 | Active not recruiting | NCT07349615 |
| Mar 2027 | BlueRock Therapeutics | bemdaneprocel, Sham surgeryA Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Parkinsons Disease (PD) | Phase 3 | Recruiting | NCT06944522 |
| Mar 2027 | Sino Biopharmaceutical Limited | TQB3473 TabletsA Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Phase 3 | Recruiting | NCT06900920 |
| Mar 2027 | Sino Biopharmaceutical Limited | TQC3721 Suspension for inhalationEvaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | NCT07147946 |
| Mar 2027 | Dompé Farmaceutici S.p.A | DFL24498, dexamethasone sodium phosphate (DSP) ophthalmic solutionAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC | Atopic Keratoconjunctivitis | Phase 3 | Recruiting | NCT07395232 |
| Mar 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 injection, Semaglutide InjectionA Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Obesity | Phase 3 | Active not recruiting | NCT07285902 |
| Mar 2027 | Grace Science, LLC | GS-100Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency | NGLY1 Deficiency | Phase 3 | Active not recruiting | NCT06199531 |
| Mar 2027 | Ionis Pharmaceuticals Inc | OlezarsenCORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | Severe Hypertriglyceridemia | Phase 3 | Active not recruiting | NCT05681351 |
| Mar 2027 | Jiangsu Hengrui Medicine | Rezvilutamide Tablets, Enzalutamide Soft CapsulesA Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | NCT07241416 |
| Mar 2027 | Madrigal Pharmaceuticals, INC. | ResmetiromA Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAEST… | Non-Alcoholic Fatty Liver Disease | Phase 3 | Active not recruiting | NCT04951219 |
| Mar 2027 | Megalabs | Experimental: Epoetin alfa Megalabs® Erythropoietin inject…, Active comparator: European Union licenced epoetin alfaComparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients | Anemia of Chronic Kidney Disease | Phase 3 | Not yet recruiting | NCT06352138 |
| Mar 2027 | Merz Therapeutics | XeominA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | Chronic Migraine | Phase 3 | Active not recruiting | NCT07018713 |
| Mar 2027 | Merz Therapeutics | XeominA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | Episodic Migraine | Phase 3 | Active not recruiting | NCT07018700 |
| Mar 2027 | Ocular Therapeutix, Inc | Single intravitreal injection of axitinib hydrogel implant…, Intravitreal injection of axitinib hydrogel implant follow…, Sham/mock procedure of intravitreal injection followed by …A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | Non-Proliferative Diabetic Retinopathy | Phase 3 | Recruiting | NCT07235085 |
| Mar 2027 | Qilu Pharmaceutical Co., Ltd. | 1.5% QLM3003 ointment, 2% QLM3003 ointmentEfficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | Atopic Dermatitis | Phase 3 | Recruiting | NCT06880276 |
| Mar 2027 | Quetzal Therapeutics | QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRAPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia and 3 more | Phase 3 | Recruiting | NCT07504458 |
| Mar 2027 | Seattle Project Corporation | GRT-C901, GRT-R902, Atezolizumab and 3 moreA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Canc… | Colorectal Neoplasms | Phase 2/3 | Active not recruiting | NCT05141721 |
| Mar 2027 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQC2731 injectionClinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | Recruiting | NCT07107256 |
| Mar 2027 | Sinovac Biotech | Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3A Lot-to-Lot Consistency Clinical Trial of PCV13 | Pneumococcal Infectious Diseases | Phase 3 | Not yet recruiting | NCT07832500 |
| Mar 2027 | Stoke Therapeutics, Inc. | zorevunersen, Sham ComparatorA Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | Dravet Syndrome | Phase 3 | Active not recruiting | NCT06872125 |
| Mar 2027 | Jiangsu Hengrui Medicine | SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection and 1 moreA Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | NCT06929624 |
| Mar 2027 | Swedish Orphan Biovitrum | Efanesoctocog alfaStudy to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | Haemophilia A (Moderate or Severe) | Phase 3 | Active not recruiting | NCT06716814 |
| Mar 2027 | UroGen Pharma Ltd. | UGN-104A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | Phase 3 | Recruiting | NCT06774131 |
| Mar 2027 | Vaxcyte, Inc. | 31-valent pneumococcal conjugate vaccine, PCV20Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | Pneumococcal Vaccines | Phase 3 | Active not recruiting | NCT07425392 |
| Mar 2027 | Vaxcyte, Inc. | 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | Pneumococcal Vaccines | Phase 3 | Active not recruiting | NCT07365826 |
| Mar 2027 | Vor Biopharma Inc. | TelitaciceptA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | NCT06456580 |
| Mar 2027 | Argenx SE | Efgartigimod IVEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasth… | Generalized Myasthenia Gravis | Phase 2/3 | Recruiting | NCT04833894 |
| Mar 1, 2027 | Aragon Pharmaceuticals, Inc. | Apalutamide, Bicalutamide, GnRH (agonist) and 1 moreAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | Prostatic Neoplasms | Phase 3 | Active not recruiting | NCT02531516 |
| Mar 1, 2027 | EyeBiotech Ltd. | Remigromig, RanibizumabA Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Phase 2/3 | Active not recruiting | NCT06957080 |
| Mar 1, 2027 | GSK | DepemokimabA Study of Depemokimab in Participants of 6 to 11 Years of Age | Asthma | Phase 3 | Recruiting | NCT07671001 |
| Mar 1, 2027 | Novo | CagriSema (Cagrilintide B and Semaglutide I)A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Obesity | Phase 3 | Active not recruiting | NCT07011667 |
| Mar 1, 2027 | Smilebiotek Zhuhai Limited | QA108 granulesQA108 Phase III Study in Subjects With Intermediate AMD | Intermediate Age-Related Macular Degeneration | Phase 3 | Recruiting | NCT07189169 |
| Mar 1, 2027 | Zero Point Five Therapeutics | ZP5-9676 600 mg dosePhase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676… | Soil-Transmitted Helminthiasis (STH) | Phase 3 | Recruiting | NCT06128447 |
| Mar 7, 2027 | Hansoh Pharmaceutical Group | HS-20089, Paclitaxel, Doxorubicin and 1 moreHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | Phase 3 | Recruiting | NCT06855069 |
| Mar 8, 2027 | Celltrion | CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dex… | Refractory or Relapsed Multiple Myeloma | Phase 3 | Active not recruiting | NCT06952478 |
| Mar 9, 2027 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | FRSW107Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. | Severe Hemophilia A | Phase 3 | Active not recruiting | NCT07684898 |
| Mar 9, 2027 | UCB | bimekizumabA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | NCT06506916 |
| Mar 11, 2027 | Bristol-Myers Squibb | Nivolumab, IpilimumabA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Renal Cell Carcinoma | Phase 3 | Active not recruiting | NCT03873402 |
| Mar 13, 2027 | Rhythm Pharmaceuticals, Inc. | SetmelanotideA Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form and 4 more | Phase 3 | Recruiting | NCT06760546 |
| Mar 14, 2027 | Zai Lab (Shanghai) Co., Ltd. | ZL-1109 (VRDN-003)A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | NCT07211776 |
| Mar 16, 2027 | Takeda Pharmaceutical Company | TAK-755A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Active not recruiting | NCT04683003 |
| Mar 17, 2027 | Pfizer | tofacitinibEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | Phase 3 | Active not recruiting | NCT04624230 |
| Mar 19, 2027 | Applied Biology, Inc. | DA-001, Phenylephrine, DA-001 Topical + DA-005 Oral (HIF-1α supplement) and 3 moreClinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | Telogen Effluvium, Female Pattern Hair Loss and 4 more | Phase 2/3 | Not yet recruiting | NCT06648850 |
| Mar 22, 2027 | Regeneron Pharmaceuticals | fianlimab, cemiplimab, relatlimab+nivolumabA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to… | Melanoma | Phase 3 | Recruiting | NCT06246916 |
| Mar 25, 2027 | Johnson & Johnson | GuselkumabA Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | Fistulizing Crohns Disease, Perianal Crohns Disease | Phase 3 | Active not recruiting | NCT05347095 |
| Mar 25, 2027 | Sanofi | Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants Wit… | Hemophilia | Phase 3 | Active not recruiting | NCT05662319 |
| Mar 26, 2027 | Lundbeck | EptinezumabA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | Chronic Migraine in Children | Phase 3 | Recruiting | NCT04965675 |
| Mar 26, 2027 | Novartis | IanalumabPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS… | Systemic Lupus Erythematosus | Phase 3 | Active not recruiting | NCT05639114 |
| Mar 26, 2027 | Shanghai JMT-Bio Inc. | JMT101 Injection, Osimertinib tablet, Cisplatin injection and 1 moreJMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung … | Local Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | NCT06380348 |
| Mar 28, 2027 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | quadrivalent recombinant norovirus vaccine (Pichia pastoris)Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) | Acute Gastroenteropathy Due to Norovirus | Phase 3 | Active not recruiting | NCT06524947 |
| Mar 30, 2027 | Hansoh Pharmaceutical Group | HS-20094 Injection, Dulaglutide InjectionA Phase 3 Study of HS-20094 in Patients With T2DM | Type 2 Diabetes | Phase 3 | Not yet recruiting | NCT07156539 |
| Mar 30, 2027 | Hansoh Pharmaceutical Group | HS-20094 InjectionA Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | Type 2 Diabetes | Phase 3 | Not yet recruiting | NCT07156500 |
| Mar 30, 2027 | Shin Poong Pharmaceutical Co. Ltd. | SP-8203Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care | Ischemic Stroke | Phase 3 | Recruiting | NCT06660719 |
| Mar 31, 2027 | Ascentage Pharma Group International | OlverembatinibA Study of Olverembatinib in SDH-deficient GIST. | GIST | Phase 3 | Recruiting | NCT06640361 |
| Mar 31, 2027 | Hangzhou Sumgen Biotech Co., Ltd. | SG301 Injection, pomalidomide, dexamethasoneA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractor… | Relapsed/Refractory Multiple Myeloma | Phase 3 | Recruiting | NCT06508983 |
| Mar 31, 2027 | Hansoh Pharmaceutical Group | HS-20137A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis | Moderate-to-severe Plaque Psoriasis | Phase 3 | Not yet recruiting | NCT06844799 |
| Mar 31, 2027 | Roche Holding | Atezolizumab, Trastuzumab Emtansine, TrastuzumabA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… | Breast Cancer | Phase 3 | Active not recruiting | NCT04873362 |
| Mar 31, 2027 | Roche Holding | SatralizumabA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquapo… | Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | NCT05199688 |
| Mar 31, 2027 | Kissei Pharmaceutical | KPS-0373Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration | Spinocerebellar Degeneration | Phase 3 | Active not recruiting | NCT07040137 |
| Mar 31, 2027 | Natureceuticals Sdn Bhd | Nuvastatic™Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy | Fatigue, Colon Cancer | Phase 3 | Recruiting | NCT07669519 |
| Mar 31, 2027 | Neuraptive Therapeutics Inc. | NTX-001 (PEG-Fusion)This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacera… | Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI) | Phase 3 | Recruiting | NCT06616025 |
| Mar 31, 2027 | Newron Pharmaceuticals SPA | Evenamide 15 mg bidEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Treatment-resistant Schizophrenia | Phase 3 | Recruiting | NCT07184619 |
| Mar 31, 2027 | Novartis | CTL019Study of Out of Specification for Tisagenlecleucel | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | NCT04094311 |
| Mar 31, 2027 | Pfizer | Ritlecitinib, Ritlecitinib 100 mgA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | Vitiligo | Phase 3 | Active not recruiting | NCT06163326 |
| Mar 31, 2027 | Pierre Fabre Medicament | Encorafenib and BinimetinibAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | Melanoma | Phase 3 | Active not recruiting | NCT05270044 |
| Mar 31, 2027 | Regenerative Ocular Immunobiologics LLC | d-MAPPS™ Ophthalmic Solution, Matching vehicle controlStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | oGVHD, Ocular Graft Versus Host Disease | Phase 3 | Recruiting | NCT07776210 |
| Mar 31, 2027 | Sinovac Biotech | SNA02-48, Human tetanus immunoglobulin (HTIG)A Phase Ⅲ Clinical Study of SNA02-48 Injection | Tetanus | Phase 3 | Not yet recruiting | NCT07633119 |
| Mar 31, 2027 | TuHURA Biosciences, Inc./NV | IFx-Hu2.0, PembrolizumabPlacebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merke… | Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | Recruiting | NCT06947928 |
| Mar 31, 2027 | Viatris | CenerimodA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Phase 3 | Active not recruiting | NCT05648500 |
| Mar 2027 | 4D Molecular Therapeutics, Inc. | 4D-150 IVT, Aflibercept IVT4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | Neovascular (Wet) Age-Related Macular Degeneration | Phase 1/2 | Recruiting | NCT05197270 |
| Mar 2027 | AbbVie | Livmoniplimab, Budigalimab, Docetaxel and 2 moreStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV… | Urothelial Carcinoma | Phase 2 | Active not recruiting | NCT06632951 |
| Mar 2027 | AbbVie | ABBV-932Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | Bipolar I or II Disorder | Phase 2 | Active not recruiting | NCT07220460 |
| Mar 2027 | Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics | ACCG-2671First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671 | Obesity | Phase 1/2 | Recruiting | NCT07815678 |
| Mar 2027 | Actimed Therapeutics Ltd | (S)-pindolol benzoate, SemaglutideA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide … | Obesity, Muscle Loss | Phase 2 | Recruiting | NCT07101939 |
| Mar 2027 | Addpharma Inc. | AD-211-L, AD-211-M, AD-211-H and 1 moreDetermining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee | Osteoarthritis of the Knees | Phase 2 | Not yet recruiting | NCT07550231 |
| Mar 2027 | Adneuris Therapeutics, Inc. | CebranopadolA Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain | Chronic Pain, Pain and 2 more | Phase 2 | Not yet recruiting | NCT07874620 |
| Mar 2027 | Aligos Therapeutics, Inc. | ALG-000184, TDFA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- … | Chronic Hepatitis B Infection | Phase 2 | Active not recruiting | NCT06963710 |
| Mar 2027 | AllRock Bio, Inc. | ROC-101A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disea… | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease | Phase 2 | Recruiting | NCT07175038 |
| Mar 2027 | Allarity Therapeutics, Inc. | 2X-121Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | Advanced Ovarian Cancer | Phase 2 | Recruiting | NCT03878849 |
| Mar 2027 | Allist Pharmaceuticals, Inc. | JAB-21822, JAB-3312Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | KRAS P.G12C, Non-small Cell Lung Cancer and 2 more | Phase 1/2 | Recruiting | NCT05288205 |
| Mar 2027 | Arch Biopartners Inc. | LSALT PeptideLSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery | Acute Kidney Injury, Cardiac Surgery | Phase 2 | Recruiting | NCT05879432 |
| Mar 2027 | Arditus Pte Ltd | ARD001A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A | Hemophilia A, Healthy Adult Participants | Phase 1/2 | Recruiting | NCT07787091 |
| Mar 2027 | Aspeya, Inc. | ASY202Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multid… | Migraine | Phase 2 | Recruiting | NCT07646613 |
| Mar 2027 | Azevan Pharmaceuticals | SRX246Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome | Aggressive Behavior in Fragile X Syndome | Phase 2 | Not yet recruiting | NCT07328529 |
| Mar 2027 | BeOne Medicines Ltd. | TacabrutidegA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | B-cell Malignancy, Marginal Zone Lymphoma and 8 more | Phase 1/2 | Recruiting | NCT05006716 |
| Mar 2027 | Beijing Biostar Pharmaceuticals Co., Ltd. | Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID, Utidelone capsule 50mg/m2/d BID and 1 morePhase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Canc… | Ovarian Cancer, Fallopian Tube Cancer and 1 more | Phase 2 | Not yet recruiting | NCT07044349 |
| Mar 2027 | Beijing InnoCare Pharma Tech Co., Ltd. | ICP-488 TabletsEvaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Recruiting | NCT07440537 |
| Mar 2027 | Beijing InnoCare Pharma Tech Co., Ltd. | ICP-322Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Prurigo Nodularis (PN) | Phase 2 | Recruiting | NCT07236099 |
| Mar 2027 | BioMarin Pharmaceutical | Vosoritide InjectionA Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Noonan Syndrome | Phase 2 | Active not recruiting | NCT06668805 |
| Mar 2027 | Biomea Fusion, Inc. | icovamenib 100mgPhase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | Type 2 Diabetes | Phase 2 | Active not recruiting | NCT07502495 |
| Mar 2027 | BonusBio Group Ltd | BonoFill-IIEnhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II | Bone Fracture | Phase 1/2 | Recruiting | NCT03024008 |
| Mar 2027 | Cellid Co., Ltd. | BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma and 1 more | Phase 1/2 | Recruiting | NCT06797986 |
| Mar 2027 | Cogent Biosciences, Inc. | CGT4859A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma and 10 more | Phase 1/2 | Active not recruiting | NCT06777316 |
| Mar 2027 | Compugen Ltd | COM701, Normal SalineA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1/2 | Active not recruiting | NCT06888921 |
| Mar 2027 | Deciphera Pharmaceuticals, Inc. | Inlexisertib, RipretinibA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | GIST | Phase 1/2 | Active not recruiting | NCT05957367 |
| Mar 2027 | Denali Therapeutics Inc. | BIIB122 225 mgSafety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Parkinson Disease | Phase 2 | Active not recruiting | NCT06602193 |
| Mar 2027 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | DM005A Study of DM005 in Patients With Advanced Solid Tumors | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck and 1 more | Phase 1/2 | Recruiting | NCT06515990 |
| Mar 2027 | Edgewise Therapeutics, Inc. | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | NCT06100887 |
| Mar 2027 | Eli Lilly and Company | Macupatide, EloralintideA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type … | Obesity, Overweight and 1 more | Phase 2 | Active not recruiting | NCT07215559 |
| Mar 2027 | Eli Lilly and Company | SolbinsiranA Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | Phase 2 | Recruiting | NCT07269210 |
| Mar 2027 | Ellipses Pharma | EP0031, Platinum chemotherapy, PemetrexedA Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | NSCLC | Phase 1/2 | Recruiting | NCT05443126 |
| Mar 2027 | Evergreen Therapeutics, Inc. | EG-007, Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection, Lenvatinib CapsulesSafety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | Advanced Endometrial Cancer | Phase 2 | Not yet recruiting | NCT05106127 |
| Mar 2027 | Faron Pharmaceuticals | Bexmarilimab, Azacitidine, VenetoclaxA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hemato… | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia and 2 more | Phase 1/2 | Active not recruiting | NCT05428969 |
| Mar 2027 | Filamon LTD | BETA-TT8 ophthalmic gel 3.8% w/vFirst in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) | Neovascular (Wet) Age-Related Macular Degeneration | Phase 1/2 | Not yet recruiting | NCT07766473 |
| Mar 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-4729 Injection, HRS-4729 Injection;A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity | Overweight or Obesity | Phase 2 | Not yet recruiting | NCT07690826 |
| Mar 2027 | Genmab A/s | EpcoritamabA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relaps… | Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | Phase 2 | Active not recruiting | NCT05451810 |
| Mar 2027 | Gilead Sciences | Domvanalimab, Zimberelimab, Paclitaxel and 1 moreStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Sta… | Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | NCT06727565 |
| Mar 2027 | Gilead Sciences | Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin and 1 moreStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (… | Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT05186974 |
| Mar 2027 | Gilead Sciences | Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR)Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children | HIV-1-infection | Phase 2 | Recruiting | NCT06749054 |
| Mar 2027 | Guangzhou Bio-gene Technology Co., Ltd | BG1805Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | Phase 1/2 | Recruiting | NCT06118788 |
| Mar 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK44459 CreamTrial of HSK44459 Cream for the Management Plaque Psoriasis | Psoriasis | Phase 1/2 | Active not recruiting | NCT07623486 |
| Mar 2027 | ImmunityBio, Inc. | AnktivaA Study to Examine Anktiva for the Treatment of COVID-19. | Long COVID, Long COVID Syndrome and 1 more | Phase 2 | Recruiting | NCT07123727 |
| Mar 2027 | Jiangsu Hengrui Medicine | SHR0302 Tablets, SHR0302 Base GelA Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo | Non-segmental Vitiligo | Phase 2 | Recruiting | NCT07251595 |
| Mar 2027 | Jiangsu Hengrui Medicine | HRS-4642A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06520488 |
| Mar 2027 | Keymed Biosciences Co.Ltd | CM313Study of CM313 in Subject With IgA Nephropathy | IgA Nephropathy | Phase 2 | Not yet recruiting | NCT06830395 |
| Mar 2027 | Kyowa Kirin | ziftomenibA Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | NCT07623616 |
| Mar 2027 | MannKind Corporation | Technosphere Insulin, Basal insulinINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Type 1 Diabetes Mellitus | Phase 2 | Recruiting | NCT07224321 |
| Mar 2027 | Myosin Therapeutics Inc. | MT-125A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma | Glioblastoma | Phase 1/2 | Not yet recruiting | NCT07604285 |
| Mar 2027 | Napo Therapeutics, S.p.A. | Crofelemer Powder for Oral SolutionSafety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (C… | Short Bowel Syndrome, Malabsorption Syndromes and 3 more | Phase 2 | Recruiting | NCT06904872 |
| Mar 2027 | Nuvation Bio Inc. | NUV-1511Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor, HER2-negative Breast Cancer and 3 more | Phase 1/2 | Active not recruiting | NCT06334432 |
| Mar 2027 | Ocugen | OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose and 1 moreStudy to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis | Retinitis Pigmentosa, Leber Congenital Amaurosis | Phase 1/2 | Active not recruiting | NCT05203939 |
| Mar 2027 | Omnix Medical Ltd | OMN6A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex | Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia | Phase 2 | Recruiting | NCT06087536 |
| Mar 2027 | PepGen Inc. | PGN-EDODM1A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | Myotonic Dystrophy 1 | Phase 2 | Recruiting | NCT06667453 |
| Mar 2027 | PhenoNet, Inc. | Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Recruiting | NCT07142291 |
| Mar 2027 | RDC Clinical Pty Ltd | TRPTI 300mgGut Microbiome and Metabolic Health Study | Healthy Volunteers | Phase 2 | Recruiting | NCT07457723 |
| Mar 2027 | Retension Pharmaceuticals, Inc. | RTN-001A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Uncontrolled Hypertension | Phase 2 | Recruiting | NCT07142356 |
| Mar 2027 | Ribotek Biopharmaceuticals (Shandong) Co., Ltd | RBD5044RBD5044 in Chinese Participants With Hypertriglyceridemia | Hypertriglyceridemia | Phase 2 | Active not recruiting | NCT07587788 |
| Mar 2027 | Seaport Therapeutics, Inc. | SPT-300A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious D… | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Recruiting | NCT07065240 |
| Mar 2027 | Jiangsu Hengrui Medicine | HRS-1893 TabletA Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Phase 2 | Recruiting | NCT07269717 |
| Mar 2027 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | LW231Study of LW231 in Participants With Chronic Hepatitis B | Chronic HBV Infection | Phase 1/2 | Recruiting | NCT07179575 |
| Mar 2027 | Shanghai Minwei Biotechnology Co., Ltd | MWN109 1, MWN109 2, MWN109 3 and 2 morePhase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Recruiting | NCT07801820 |
| Mar 2027 | Jiangsu Hengrui Medicine | SHR-A2102, Adebrelimab, Cetuximab and 2 moreA Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinom… | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1/2 | Recruiting | NCT07059221 |
| Mar 2027 | TILT Biotherapeutics Ltd. | TILT-123, pembrolizumab, pegylated liposomal doxorubicinOncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (… | Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer and 7 more | Phase 1/2 | Active not recruiting | NCT05271318 |
| Mar 2027 | Tarian Pharma | TAR-0520 gelTAR-0520 Gel in Hand and Foot Syndrome | Hand and Foot Syndrome | Phase 2 | Not yet recruiting | NCT07457671 |
| Mar 2027 | Twinpig Biolab, Inc. | TB511, KeytrudaClinical Trial of TB511 in Advanced Solid Tumors | NSCLC, Prostate Cancer and 2 more | Phase 1/2 | Not yet recruiting | NCT06400160 |
| Mar 2027 | Vanda Pharmaceuticals Inc. | VCA-894ATreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | Phase 1/2 | Active not recruiting | NCT07223632 |
| Mar 2027 | Vima Therapeutics | VIM0423A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia | Dystonia | Phase 2 | Recruiting | NCT07304089 |
| Mar 2027 | VivaCell Biotechnology España | Etribnabdione 25 mg BID, Etribnabdione 50 mg BIDEvaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease | Peripheral Arterial Disease | Phase 2 | Not yet recruiting | NCT06774040 |
| Mar 2027 | Walden Biosciences | WAL0921Study of WAL0921 in Patients With Glomerular Kidney Diseases | Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis and 3 more | Phase 2 | Recruiting | NCT06466135 |
| Mar 2027 | Argenx SE | Efgartigimod PH20 SCA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | Systemic Sclerosis (SSc) | Phase 2 | Active not recruiting | NCT06655155 |
| Mar 1, 2027 | 60 Degrees Pharmaceuticals, INC. | TafenoquineOral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | Babesiosis | Phase 2 | Recruiting | NCT06207370 |
| Mar 1, 2027 | Hansoh Pharmaceutical Group | HS-20137An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis | Moderate-to-severe Plaque Psoriasis | Phase 2 | Recruiting | NCT07879885 |
| Mar 1, 2027 | Shenzhen Salubris Pharmaceuticals | SAL0140A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension | Uncontrolled Hypertension | Phase 2 | Recruiting | NCT07654140 |
| Mar 1, 2027 | Tharimmune Inc | NalmefeneTH104 for the Treatment of Pruritus in Primary Biliary Cholangitis | Pruritus, Primary Biliary Cholangitis | Phase 2 | Not yet recruiting | NCT06733519 |
| Mar 1, 2027 | Ukko Inc | UKK-0018UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies | Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1/2 | Recruiting | NCT07349212 |
| Mar 1, 2027 | Vaxine Pty Ltd | Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccineA Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection | Chronic Hepatitis b | Phase 1/2 | Not yet recruiting | NCT03038802 |
| Mar 1, 2027 | Verona Pharma | EnsifentrineEffect of Ensifentrine on Sputum Markers of Inflammation in COPD | COPD | Phase 2 | Active not recruiting | NCT05270525 |
| Mar 3, 2027 | Freya Biosciences ApS | FB 301, Chlorhexidine 0.5%, metronidazole 500 mgChlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial | Bacterial Vaginosis (BV) | Phase 2 | Recruiting | NCT07481955 |
| Mar 5, 2027 | Boehringer Ingelheim | BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US onlyA Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Diabetic Retinopathy | Phase 2 | Recruiting | NCT06321302 |
| Mar 6, 2027 | Moderna | mRNA-1647A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Tran… | Cytomegalovirus Infection | Phase 2 | Active not recruiting | NCT05683457 |
| Mar 8, 2027 | AstraZeneca | AZD7760A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis… | Staphylococcus Aureus | Phase 1/2 | Active not recruiting | NCT06749457 |
| Mar 8, 2027 | Pfizer | PF-07275315A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Asthma | Phase 2 | Recruiting | NCT06977581 |
| Mar 9, 2027 | GSK | CamlipixantA Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) … | Irritable Bowel Syndrome | Phase 2 | Recruiting | NCT07519395 |
| Mar 10, 2027 | CSPC Pharmaceutical Group | A zoster mRNA vaccine SYS6017, Active Comparator VaccineImmunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above | Herpes Zoster | Phase 2 | Not yet recruiting | NCT07354659 |
| Mar 10, 2027 | GSK | MenABCWY vaccineSafety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | Meningitis, Meningococcal | Phase 2 | Active not recruiting | NCT05087056 |
| Mar 11, 2027 | Boehringer Ingelheim | BI 765423A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Stan… | Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | NCT07036523 |
| Mar 12, 2027 | ENA Respiratory Pty Ltd | INNA-051A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults… | Viral Respiratory Infection, Viral Respiratory Illnesses | Phase 2 | Recruiting | NCT07222670 |
| Mar 12, 2027 | Sinocelltech Ltd. | SCT650CEfficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | NCT07244510 |
| Mar 12, 2027 | Travere Therapeutics, Inc. | SparsentanStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Focal Segmental Glomerulosclerosis, Minimal Change Disease and 3 more | Phase 2 | Recruiting | NCT05003986 |
| Mar 12, 2027 | Vertex Pharmaceuticals | VX-264A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | Type 1 Diabetes | Phase 1/2 | Active not recruiting | NCT05791201 |
| Mar 13, 2027 | Otsuka Pharmaceutical | SibeprenlimabA Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | Sjogren Disease | Phase 2 | Active not recruiting | NCT06928142 |
| Mar 14, 2027 | Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC, LymphodepletionDual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer | Colorectal Cancer, Metastatic Colorectal Adenocarcinoma and 1 more | Phase 1/2 | Recruiting | NCT07589517 |
| Mar 14, 2027 | Beijing Biotech | EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, CyclophosphamideEGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC | Phase 1/2 | Recruiting | NCT07617805 |
| Mar 14, 2027 | Beijing Biotech | EB-MF-CAR-NK-01, Fludarabine, CyclophosphamideDual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma | Malignant Pleural Mesotheliomas | Phase 1/2 | Recruiting | NCT07510815 |
| Mar 14, 2027 | Beijing Biotech | EB-DUALNK, Cyclophosphamide, FludarabineDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Phase 1/2 | Recruiting | NCT07589543 |
| Mar 14, 2027 | Beijing Biotech | EB-DT-CAR-NK, Fludarabine, CyclophosphamideDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1/2 | Recruiting | NCT07551362 |
| Mar 14, 2027 | Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, CyclophosphamideDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | Phase 1/2 | Recruiting | NCT07500220 |
| Mar 14, 2027 | Beijing Biotech | EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy and 1 morePRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors | Advanced or Metastatic Solid Tumors | Phase 1/2 | Recruiting | NCT07510828 |
| Mar 14, 2027 | Beijing Biotech | Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive careDual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Non-Small Cell Lung Cancer, Advanced/Metastatic | Phase 1/2 | Recruiting | NCT07641023 |
| Mar 14, 2027 | Beijing Biotech | EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells, Fludarabine, CyclophosphamideDual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma | Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | Phase 1/2 | Recruiting | NCT07622940 |
| Mar 14, 2027 | Beijing Biotech | EB-HC01 dual-target CARNK cells, Fludarabine, CyclophosphamideDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma and 3 more | Phase 1/2 | Recruiting | NCT07641036 |
| Mar 14, 2027 | Beijing Biotech | EB-DTNB-NK, Fludarabine, CyclophosphamideDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma | Relapsed Neuroblastoma, Refractory Neuroblastoma and 2 more | Phase 1/2 | Recruiting | NCT07502287 |
| Mar 14, 2027 | Beijing Biotech | Autologous anti-CD19 CAR-T cells, intravenous single infus…, Fludarabine, CyclophosphamideSELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1/2 | Recruiting | NCT07523542 |
| Mar 14, 2027 | Beijing Biotech | Dual-target CAR-NK cells, Lymphodepleting, Supportive careDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer and 1 more | Phase 1/2 | Recruiting | NCT07510802 |
| Mar 14, 2027 | Beijing Biotech | Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module and 5 moreAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | Phase 1/2 | Recruiting | NCT07523555 |
| Mar 14, 2027 | Carrick Therapeutics Limited | CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg)A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Solid Malignancies | Phase 1/2 | Recruiting | NCT06600789 |
| Mar 14, 2027 | Hudson Biotech | Retatrutide (LY3437943), Standardized diet and physical activity counseling through…Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | Obesity | Phase 2 | Recruiting | NCT07467447 |
| Mar 15, 2027 | Energenesis Biomedical Co., Ltd. | ENERGI-F703EB Cream, Matched vehicle creamA Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa | Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa and 2 more | Phase 2 | Recruiting | NCT07858422 |
| Mar 16, 2027 | Intra-Cellular Therapies, Inc. | ITI-1284 10 mg, ITI-1284 20 mgStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Generalized Anxiety Disorder | Phase 2 | Recruiting | NCT06480383 |
| Mar 17, 2027 | Sino Biopharmaceutical Limited | TQC2938 injectionA Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | NCT06789289 |
| Mar 18, 2027 | Bristol-Myers Squibb | BMS-986446Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alz… | Alzheimer Disease, Early Onset | Phase 2 | Active not recruiting | NCT06268886 |
| Mar 19, 2027 | GSK | Momelotinib, LuspaterceptStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Recruiting | NCT06517875 |
| Mar 20, 2027 | Medipost Co Ltd. | SMUP-IA-01(low-dose), SMUP-IA-01(mid-dose), High Hyal PlusEvaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control | Knee Osteoarthritis | Phase 2 | Active not recruiting | NCT06798727 |
| Mar 22, 2027 | Merck & Co. | Pembrolizumab, Belzutifan, LenvatinibPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Neoplasm Malignant | Phase 2 | Active not recruiting | NCT04976634 |
| Mar 23, 2027 | AstraZeneca | Trastuzumab deruxtecanA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer | Phase 2 | Active not recruiting | NCT04482309 |
| Mar 23, 2027 | Boehringer Ingelheim | Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | Diabetic Macular Edema | Phase 1/2 | Recruiting | NCT07553429 |
| Mar 23, 2027 | Innovent Biologics | IBI3002, DupilumabA Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Recruiting | NCT07399067 |
| Mar 23, 2027 | Novartis | Cryptosporidium parvum oocysts (ABO809), EDI048Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults | Cryptosporidiosis | Phase 2 | Recruiting | NCT07249463 |
| Mar 24, 2027 | Pfizer | ARV-471, AbemaciclibTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic B… | Breast Cancer | Phase 1/2 | Active not recruiting | NCT05548127 |
| Mar 25, 2027 | OrthoTrophix, Inc | TPX-100 200mg, Once weekly for 4 weeks, PBS53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis o… | Osteoarthritis (OA) of the Knee | Phase 2 | Active not recruiting | NCT06865079 |
| Mar 25, 2027 | Vertex Pharmaceuticals | VX-993, PregabalinEvaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Phase 2 | Recruiting | NCT06619860 |
| Mar 26, 2027 | Ipsen | CorabotaseA Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | Cervical Dystonia | Phase 2 | Recruiting | NCT06937931 |
| Mar 28, 2027 | CSPC Pharmaceutical Group | SYS6041A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT07744763 |
| Mar 29, 2027 | ScinnoHub Pharmaceutical Co., Ltd. | SNH-119014 dose 1, SNH-119014 dose 2A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) | Thalassemia | Phase 2 | Not yet recruiting | NCT07579949 |
| Mar 30, 2027 | Galimedix Therapeutics Inc | GAL-101A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD | Geographic Atrophy of the Macula | Phase 2 | Recruiting | NCT06659549 |
| Mar 30, 2027 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Human umbilical cord mesenchymal stem cells injection, saline solutionSafety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-S… | Arteriovenous Fistula Stenosis | Phase 1/2 | Not yet recruiting | NCT07452822 |
| Mar 30, 2027 | Sonara Health | SonaraRemotely Observed Methadone Evaluation II | Opioid Use Disorder | Phase 2 | Recruiting | NCT06338280 |
| Mar 31, 2027 | AstraZeneca | AZD4360Study for AZD4360 in Participants With Advanced Solid Tumours | Gastric Cancer, Gastroesophageal Junction Cancer and 2 more | Phase 1/2 | Active not recruiting | NCT06921928 |
| Mar 31, 2027 | BeOne Medicines Ltd. | BGB-B2033, Tislelizumab, BevacizumabA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Meta… | Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma and 3 more | Phase 1/2 | Recruiting | NCT06427941 |
| Mar 31, 2027 | Beijing Gene Key Life Technology Co., Ltd | GKL-006 injection, Nab-paclitaxel and GemcitabineA Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas | Phase 1/2 | Active not recruiting | NCT07777211 |
| Mar 31, 2027 | BioMimetix JV, LLC | BMX-001, Paclitaxel (Taxol)BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm | Phase 1/2 | Not yet recruiting | NCT06620029 |
| Mar 31, 2027 | BioRay Pharmaceutical Co., Ltd. | Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporineA Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Phase 2 | Active not recruiting | NCT06642909 |
| Mar 31, 2027 | Boehringer Ingelheim | BI 1291583Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This M… | Bronchiectasis | Phase 2 | Active not recruiting | NCT05846230 |
| Mar 31, 2027 | CG Oncology, Inc. | Cretostimogene GrenadenorepvecPhase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | High-Risk Non-Muscle-Invasive Bladder Cancer | Phase 2 | Recruiting | NCT06567743 |
| Mar 31, 2027 | CellCentric Ltd. | CCS1477, Pomalidomide, Dexamethasone and 8 moreStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | Haematological Malignancy, Acute Myeloid Leukemia and 4 more | Phase 1/2 | Recruiting | NCT04068597 |
| Mar 31, 2027 | Eisai | E7389-LF, NivolumabA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | Solid Neoplasms | Phase 1/2 | Active not recruiting | NCT04078295 |
| Mar 31, 2027 | Eisai | E7386, Lenvatinib, Doxorubicin and 1 moreA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Endometrial Neoplasms, Neoplasms and 3 more | Phase 1/2 | Active not recruiting | NCT04008797 |
| Mar 31, 2027 | Hangzhou Sumgen Biotech Co., Ltd. | SG301 InjectionStudy of SG301 for Renal AMR After Transplantation | Antibody Mediated Rejection | Phase 2 | Not yet recruiting | NCT07764627 |
| Mar 31, 2027 | Hebei Senlang Biotechnology Inc., Ltd. | S1904 CD19 CAR-TAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | B-ALL | Phase 2 | Recruiting | NCT07244406 |
| Mar 31, 2027 | Roche Holding | Englumafusp alfa, Obinutuzumab, Glofitamab and 1 moreA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab an… | Lymphoma, Non-Hodgkin | Phase 1/2 | Active not recruiting | NCT04077723 |
| Mar 31, 2027 | Kither Biotech Srl | KIT2014A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD | Chronic Obstructive Pulmonary Disease (COPD) | Phase 1/2 | Recruiting | NCT07668518 |
| Mar 31, 2027 | Merakris Therapeutics | MTX-001 (human amniotic fluid)MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers | Venous Stasis Ulcer, Venous Leg Ulcer | Phase 2 | Recruiting | NCT04647240 |
| Mar 31, 2027 | Merck & Co. | Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kgPosaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) | Invasive Fungal Infection | Phase 2 | Recruiting | NCT04665037 |
| Mar 31, 2027 | Pfizer | ATM-AVI, BATStudy of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections | Gram-negative Bacterial Infections | Phase 2 | Recruiting | NCT05639647 |
| Mar 31, 2027 | Remedy | MDMA assisted psychotherapy, PsychotherapyMDMA-Assisted CBCT for PTSD vs CBCT RCT | Post Traumatic Stress Disorder | Phase 2 | Recruiting | NCT06044675 |
| Mar 31, 2027 | Satellos Bioscience Inc. | SAT-3247Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | Duchenne Muscular Dystrophy, Duchenne and 3 more | Phase 2 | Active not recruiting | NCT07287189 |
| Mar 31, 2027 | Shanghai AbelZeta Ltd. | Prizloncabtagene autoleucelA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma | Relapsed/Refractory Large B-Cell Lymphoma | Phase 1/2 | Recruiting | NCT05800977 |
| Mar 31, 2027 | Shanghai Guangsheng Biopharmaceutical Co., Ltd | Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection, Cisplatin for injectionCosiporfin Sodium for Injection Photodynamic Therapy | Biliary Tract Cancers (BTC) | Phase 2 | Recruiting | NCT07398339 |
| Mar 31, 2027 | Shanghai Institute Of Biological Products | SIBP-A16 injection, Nirsevimab, SIBP-A16 buffer solutionPhase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants | Respiratory Syncytial Virus (RSV) | Phase 1/2 | Not yet recruiting | NCT07363837 |
| Mar 31, 2027 | Tango Therapeutics, Inc. | TNG456, abemaciclibSafety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme and 5 more | Phase 1/2 | Recruiting | NCT06810544 |
| Mar 31, 2027 | Teclison Ltd. | TATE and pembrolizumab, TAS-102 pill, Regorafenib PillTATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Colorectal Cancer; Lung Cancer | Phase 2 | Recruiting | NCT04701476 |
| Mar 31, 2027 | Urmila DIwekar | Opt-IVF, controlOpt-IVF for Personalized Medicine for Normal Responders | Ivf | Phase 1/2 | Recruiting | NCT07856082 |
| Mar 31, 2027 | Vivus | VI-0609, BiCNUA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | Lymphoma, Non-Hodgkin Lymphoma and 1 more | Phase 2 | Recruiting | NCT06915246 |
| Mar 31, 2027 | Vast Therapeutics | ALX1Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis | Bronchiectasis Adult | Phase 2 | Not yet recruiting | NCT07731919 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.